Amylyx Pharmaceuticals (AMLX) said Wednesday it has started dosing participants in its phase 3 trial for avexitide, a treatment for post-bariatric hypoglycemia, a condition where blood sugar drops too low after weight-loss surgery.
The trial will study about 75 patients who had Roux-en-Y gastric bypass surgery, across 20 sites in the US to measure how well avexitide reduces moderate to severe low blood sugar events in 16 weeks, the company said.
Patients will be randomly assigned to receive either a daily 90 mg dose of avexitide or a placebo, and those who finish the 16-week double-blind phase can join a 32-week open-label extension, it added.
Amylyx said it expects to finish enrolling participants in 2025 and release top-line data in H1 2026.
The company also said its cash reserves should last through the end of 2026.
Shares of the company were up about 3% in recent trading.
Price: 5.06, Change: +0.16, Percent Change: +3.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.